Evidence map›Paper›PMID 35951245›Full record

ReviewCurrent heart failure reports2022

Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.

Christian Olivo Freites, Hendrik Sy, Amal Gharamti, Nelson I Agudelo Higuita, Carlos Franco-Paredes, José Antonio Suárez, Andrés F Henao-Martínez

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Clinical Progression of Cardiac ChronicPathogens (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Review
  5. The epidemiology of Chagas disease in the Americas.Lancet regional health. Americas · 2024
    Review
  6. Review
  7. Review
  8. The intersection of hostMicrobiology and molecular biology reviews : MMBR · 2024
    Review
  9. Article
  10. Signatures of CD4Frontiers in immunology · 2024
    Article
  11. Current tropical medicine reports · 2023
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 7 institutions in 3 countries.

Christian Olivo FreitesDivision of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Hendrik SyInternal Medicine Department, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Amal GharamtiInternal Medicine Department, Yale-Waterbury Hospital, Yale School of Medicine, New Haven, CT, USA.
Nelson I Agudelo HiguitaUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Carlos Franco-ParedesFederico Gómez, Hospital Infantil de México, Mexico City, México.
José Antonio SuárezClinical Research Department, Investigador SNI Senacyt Panamá, Instituto Conmemorativo Gorgas de Estudios de La Salud, Panamá City, Republic of Panama.
Andrés F Henao-MartínezDepartment of Medicine, University of Colorado Anschutz Medical Campus, 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO, USA. andres.henaomartinez@cuanschutz.edu.
Hospital Infantil de México Federico Gómez · MXIcahn School of Medicine at Mount Sinai · USInstituto Conmemorativo Gorgas de Estudios de la Salud · PAUniversity of California, Los Angeles · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Oklahoma Health Sciences Center · USWaterbury Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of the reviewChagas disease is a neglected anthropozoonosis of global importance with significant cardiovascular-associated mortality. This review focuses on the Trypanosoma cruzi reinfections' role in chronic Chagas cardiomyopathy pathogenesis. We discuss and summarize the available data related to pathology, pathogenesis, diagnosis, and treatment of reinfections. RECENT

findingsReinfections influence the genetic and regional diversity of T. cruzi, tissue tropism, modulation of the host's immune system response, clinical manifestations, the risk for congenital infections, differences in diagnostics performances, response to antiparasitic therapy, and the natural history of the disease. Animal models suggest that reinfections lead to worse outcomes and increased mortality, while other studies showed an association between reinfections and lower parasitemia levels and subsequent infection protection. In some regions, the human risk of reinfections is 14% at 5 years. Evidence has shown that higher anti-T. cruzi antibodies are correlated with an increased rate of cardiomyopathy and death, suggesting that a higher parasite exposure related to reinfections may lead to worse outcomes. Based on the existing literature, reinfections may play a role in developing and exacerbating chronic Chagas cardiomyopathy and are linked to worse outcomes. Control efforts should be redirected to interventions that address structural poverty for the successful and sustainable prevention of Chagas disease.

Indexed as

Chagas CardiomyopathyChagas DiseaseHeart FailureAnimalsAntiparasitic AgentsHumansReinfectionAntiparasitic AgentsAmerican TrypanosomiasisChagasReinfectionTrypanosoma cruzi

Identifiers

PMID35951245
OpenAlexW4291017856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.